About Aravive, inc.
Aravive, Inc. is a biopharmaceutical company that focuses on developing innovative therapies for the treatment of cancer and other diseases. The company's mission is to improve the lives of patients by providing them with effective and safe treatments that target specific molecular pathways involved in disease progression.
Aravive, Inc. was founded in 2015 by a team of experienced scientists and entrepreneurs who shared a common vision of using cutting-edge technologies to develop novel therapeutics for cancer and other diseases. Since its inception, the company has made significant progress in advancing its pipeline of drug candidates through preclinical and clinical development.
One of Aravive's most promising drug candidates is AVB-500, a first-in-class decoy protein that targets GAS6-AXL signaling pathway, which plays a critical role in promoting tumor growth and metastasis. AVB-500 has shown promising results in preclinical studies as well as early-stage clinical trials for various types of solid tumors.
In addition to AVB-500, Aravive is also developing other drug candidates targeting different molecular pathways involved in cancer progression. These include ARV-110, an oral small molecule inhibitor targeting the androgen receptor pathway for the treatment of prostate cancer; ARV-471, an oral small molecule inhibitor targeting estrogen receptor alpha (ERα) degradation for the treatment of breast cancer; and ARV-1906, an intravenous small molecule inhibitor targeting c-MET signaling pathway for the treatment of solid tumors.
Aravive's approach to drug development is based on deep understanding of disease biology combined with state-of-the-art technologies such as high-throughput screening assays, structural biology analysis, computational modeling, and biomarker discovery. The company collaborates with leading academic institutions as well as pharmaceutical companies to accelerate its research programs.
Aravive's management team consists of seasoned executives with extensive experience in biotech industry including Dr. Gail McIntyre (CEO), Dr. Ray Tabibiazar (CFO), and Dr. Reshma Rangwala (CMO). The company is headquartered in Houston, Texas, with additional offices in California and Switzerland.
Aravive's innovative approach to drug development has attracted significant attention from investors and the scientific community. The company has raised over $100 million in funding from leading venture capital firms such as Canaan Partners, 5AM Ventures, and OrbiMed Advisors. Aravive has also received several awards and recognitions for its groundbreaking research including the Frost & Sullivan 2020 North American Technology Innovation Award for Best Practices in Precision Oncology.
In conclusion, Aravive, Inc. is a biopharmaceutical company that is dedicated to developing innovative therapies for cancer and other diseases using cutting-edge technologies and deep understanding of disease biology. With a promising pipeline of drug candidates targeting specific molecular pathways involved in disease progression, Aravive is poised to make a significant impact on the field of oncology and improve the lives of patients worldwide.